

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM839035

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Eisai Inc.		03/31/2019	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Concordia Pharmaceuticals Inc.		
Street Address:	8-10 Avenue de la Gare		
City:	Luxembourg		
State/Country:	LUXEMBOURG		
Postal Code:	L-1610		
Entity Type:	Private Limited Liability Company: LUXEMBOURG		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	1753114	SALAGEN	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	meghna.prasad@bakerbotts.com		
Correspondent Name:	Meghna Prasad		
Address Line 1:	30 Rockefeller Center		
Address Line 4:	New York, NEW YORK 10112		
NAME OF SUBMITTER:	Meghna Prasad		
SIGNATURE:	/Meghna Prasad/		
DATE SIGNED:	09/13/2023		
Total Attachments: 25			
source=Eisai to AMIL CPI MPGL Trademark Assignment Agreement#page1.tif			
source=Eisai to AMIL CPI MPGL Trademark Assignment Agreement#page2.tif			
source=Eisai to AMIL CPI MPGL Trademark Assignment Agreement#page3.tif			
source=Eisai to AMIL CPI MPGL Trademark Assignment Agreement#page4.tif			
source=Eisai to AMIL CPI MPGL Trademark Assignment Agreement#page5.tif			
source=Eisai to AMIL CPI MPGL Trademark Assignment Agreement#page6.tif			
source=Eisai to AMIL CPI MPGL Trademark Assignment Agreement#page7.tif			

CH \$40.00 1753114

source=Eisai to AMIL CPI MPGL Trademark Assignment Agreement#page8.tif
source=Eisai to AMIL CPI MPGL Trademark Assignment Agreement#page9.tif
source=Eisai to AMIL CPI MPGL Trademark Assignment Agreement#page10.tif
source=Eisai to AMIL CPI MPGL Trademark Assignment Agreement#page11.tif
source=Eisai to AMIL CPI MPGL Trademark Assignment Agreement#page12.tif
source=Eisai to AMIL CPI MPGL Trademark Assignment Agreement#page13.tif
source=2019 03 31 CPI MPGL AMIL Confirmatory Trademark Assignment SALAGEN_Active_42795721_1
(003)#page1.tif
source=2019 03 31 CPI MPGL AMIL Confirmatory Trademark Assignment SALAGEN_Active_42795721_1
(003)#page2.tif
source=2019 03 31 CPI MPGL AMIL Confirmatory Trademark Assignment SALAGEN_Active_42795721_1
(003)#page3.tif
source=2019 03 31 CPI MPGL AMIL Confirmatory Trademark Assignment SALAGEN_Active_42795721_1
(003)#page4.tif
source=2019 03 31 CPI MPGL AMIL Confirmatory Trademark Assignment SALAGEN_Active_42795721_1
(003)#page5.tif
source=2019 03 31 CPI MPGL AMIL Confirmatory Trademark Assignment SALAGEN_Active_42795721_1
(003)#page6.tif
source=2019 03 31 CPI MPGL AMIL Confirmatory Trademark Assignment SALAGEN_Active_42795721_1
(003)#page7.tif
source=2019 03 31 CPI MPGL AMIL Confirmatory Trademark Assignment SALAGEN_Active_42795721_1
(003)#page8.tif
source=2019 03 31 CPI MPGL AMIL Confirmatory Trademark Assignment SALAGEN_Active_42795721_1
(003)#page9.tif
source=2019 03 31 CPI MPGL AMIL Confirmatory Trademark Assignment SALAGEN_Active_42795721_1
(003)#page10.tif
source=2019 03 31 CPI MPGL AMIL Confirmatory Trademark Assignment SALAGEN_Active_42795721_1
(003)#page11.tif
source=2019 03 31 CPI MPGL AMIL Confirmatory Trademark Assignment SALAGEN_Active_42795721_1
(003)#page12.tif

TRADEMARK ASSIGNMENT AGREEMENT

This Trademark Assignment Agreement (this "**Trademark Assignment**") is made as of this 31st day of March, 2019, by and between (i) Eisai Inc., a Delaware corporation ("**Seller**"), and (ii) Concordia Pharmaceuticals Inc., a *societe a responsabilite limitee* (private limited liability company) duly continued and validly existing under the laws of the Grand-Duchy of Luxembourg, having its registered office at 8-10 Avenue de la Gare - L-1610 Luxembourg, Grand-Duchy of Luxembourg, and registered with the Registre de commerce et des societes, Luxembourg (register of trade and companies), by way of its Barbados branch, carrying on business at 5 Canewood Business Centre, St. Michael, Barbados, BB 11005, Mercury Pharma Group Limited, a private limited company incorporated in England and Wales, whose registered office is at Capital House, 1st Floor, 85 King William Street, London EC4N 7BL, and Amdipharm Mercury International Limited, a private limited company incorporated in Jersey, whose registered office is at 11-15 Seaton Place, St. Helier, Jersey, JE4 0QH (collectively, "**Buyer**"). Seller and Buyer are sometimes referred to herein individually as a "**Party**" and collectively as the "**Parties**."

RECITALS

WHEREAS, Seller is the owner in the applicable jurisdiction of the marks, registrations and applications set forth on Schedule A attached hereto and made part hereof and the goodwill of the business associated with and symbolized by such marks (collectively, the "**US Exclusive Product Trademarks**");

WHEREAS, Seller, Buyer and certain of Buyer's Affiliates have entered into that certain Asset Purchase Agreement, dated as of March 31, 2019 (the "**Asset Purchase Agreement**"); and

WHEREAS, in connection with the Asset Purchase Agreement, Buyer and certain of Buyer's Affiliates agreed to acquire from Seller, and Seller has agreed to sell, transfer, convey, assign and deliver to Buyer, all of Seller's rights, title and interests in and to the Exclusive Product Trademarks, which include the US Exclusive Product Trademarks, together with the goodwill of the business associated with and symbolized by the Exclusive Product Trademarks.

NOW, THEREFORE, in consideration of the mutual benefits to be derived from this Trademark Assignment and of the representations, warranties, conditions, agreements and promises contained in the Asset Purchase Agreement, this Trademark Assignment and the other Ancillary Agreements, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

1. **Defined Terms.** Unless otherwise specifically provided herein, capitalized terms used in this Trademark Assignment and not otherwise defined herein shall have the respective meanings ascribed thereto in the Asset Purchase Agreement.

2. **Conveyance and Acceptance of Exclusive Product Trademarks.** In accordance with the provisions of the Asset Purchase Agreement, Seller hereby sells, assigns, transfers, conveys and delivers to Buyer, all of its rights, title and interest in and to the US Exclusive Product Trademarks in the jurisdiction set forth opposite each such US Exclusive Product Trademark on Schedule A.
3. **Recordation.** Seller hereby authorizes Buyer to record this Trademark Assignment with the U.S. Patent and Trademark Office and other relevant Governmental Authorities. All costs and expenses, including Third Party filing and recordation fees and other disbursements, associated with the conveyance of the US Exclusive Product Trademarks and with the recordation of this Trademark Assignment shall be borne solely by Buyer.
4. **Asset Purchase Agreement Controls.** Notwithstanding any other provision of this Trademark Assignment to the contrary, nothing contained herein shall in any way supersede, modify, replace, amend, change, rescind, waive, exceed, expand, enlarge or in any way affect the provisions, including warranties, covenants, agreements, conditions, representations or, in general any of the rights and remedies, or any of the obligations of Buyer or Seller set forth in the Asset Purchase Agreement. This Trademark Assignment is subject to, and governed entirely in accordance with, the terms and conditions of the Asset Purchase Agreement. Nothing contained herein is intended to modify or supersede any of the provisions of the Asset Purchase Agreement, except as set forth in Section 6(a).
5. **Further Assurances.** Seller agrees, at Buyer's expense, to take such further action and to execute and deliver such additional instruments and documents as Buyer may reasonably request to carry out and fulfill the purposes and intent of this Trademark Assignment, including signing all papers and documents, taking all lawful oaths and doing all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of trademarks or applications of US Exclusive Product Trademarks.
6. **Miscellaneous.**
 - (a) **Expenses.** All costs and expenses associated with the conveyance under this Trademark Assignment of all rights, title and interest of Seller in and to the US Exclusive Product Trademarks shall be borne solely by Buyer.
 - (b) **Counterparts.** This Trademark Assignment may be executed in any number of counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement. Delivery of an executed counterpart of a signature page of this Trademark Assignment by facsimile or other electronic transmission shall be effective as delivery of a manually executed original counterpart of this Trademark Assignment.

[Signature page follows]

IN WITNESS WHEREOF, the undersigned have duly executed this Trademark Assignment, as of the date first above written.

EISAI INC.

By: Shaji Procida
Name: Shaji Procida
Title: President & Chief Operating Officer

[Signature Page to Trademark Assignment Agreement]

STATE OF New Jersey
COUNTY OF Bergen

On this 27th day of March, 2019, before me personally appeared Shaji Pradeep to me personally known, who, being duly sworn, did say that he/she is the Resident CEO of Eisai Inc. and that he/she duly executed the foregoing instrument for and on behalf of Eisai Inc. being duly authorized to do so and that said individual acknowledged said instrument to be the free act and deed of said company.

Nancy H. Leto
Notary Public
Expiration Date: _____

NANCY H. LETO
NOTARY PUBLIC
STATE OF NEW JERSEY
ID # 2281992
MY COMMISSION EXPIRES DEC. 14, 2021

CONCORDIA PHARMACEUTICALS INC.

By: 

Name: Robert Ford
Title: Managing Director, VP Legal Affairs

MERCURY PHARMA GROUP LIMITED

By: _____

Name:
Title:

AMDIPHARM MERCURY INTERNATIONAL LIMITED

By: _____

Name:
Title:

[Signature Page to Eisai-Buyer Trademark Assignment Agreement]

PARISH OF St. Michael }


COUNTRY OF BARBADOS }

On this 29th day of March, 2019, before me personally appeared Robert Ford, ~~to me personally known~~ who, being duly sworn, did say that he/she is the Managing Director, Vice President Legal Affairs of Concordia Pharmaceuticals Inc., Barbados branch and that he/she duly executed the foregoing instrument for and on behalf of Concordia Pharmaceuticals Inc., Barbados branch being duly authorized to do so and that said individual acknowledged said instrument to be the free act and deed of said company.

Notary Public: Obunyeffens

Expiration Date: Ex-Officio

(09) ASST. REGISTRAR AND AS
SUCH A NOTARY PUBLIC IN
AND FOR BARBADOS



CONCORDIA PHARMACEUTICALS INC.

By: _____
Name:
Title:

MERCURY PHARMA GROUP LIMITED

By:  _____
Name: G. DUNCAN
Title: C.E.O.

AMDIPHARM MERCURY INTERNATIONAL
LIMITED

By: _____
Name:
Title:

[Signature Page to Eisai-Buyer Trademark Assignment Agreement]

CONCORDIA PHARMACEUTICALS INC.,
BARBADOS BRANCH

By: _____
Name:
Title:

MERCURY PHARMA GROUP LIMITED

By: _____
Name:
Title:

AMDI PHARM MERCURY INTERNATIONAL
LIMITED

By: _____
Name:
Title:

M J Culien Director

[Signature Page to Eisai-Buyer Trademark Assignment Agreement]

SCHEDULE A

US EXCLUSIVE PRODUCT TRADEMARKS

Schedule of SALAGEN Product Trademarks

Trademark Applications and Registrations:

Mark	Country	Status	App. No. Date	Reg. No. Date	Owner
SALAGEN	Albania	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Andorra	Registered	2000 19-Dec-1996	1470 19-Dec-1996	Seller
SALAGEN	Antigua and Barbuda	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Argentina	Registered	3062975 19-Jan-2011	2738487 13-Jul-2015	Seller
SALAGEN	Armenia	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Australia	Registered	715002 13-Aug-1996	715002 19-Sep-1997	Seller
SALAGEN	Australia	IR Accepted	988334 12-Nov-2003	988334 (IR 817299) 12-Nov-2003	Seller
SALAGEN	Belarus	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Benelux	Registered	763095 26-Apr-1991	495933 26-Apr-1991	Seller
SALAGEN	Bhutan	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Brazil	Registered	819666394 02-Dec-1996	819666394 04-Nov-2003	Seller
SALAGEN	Bulgaria	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Canada	Registered	680671 24-Apr-1991	TMA440724 24-Mar-1995	Seller
SALAGEN	China	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Colombia	Registered	10030242 5-Mar-2010	428118 29-Jun-2011	Seller
SALAGEN	Cuba	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Denmark	Registered	3149/91 01-May-1991	2681-1993 02-Apr-1993	Seller
SALAGEN	Ecuador	Registered	2013-35199 08-Feb-2013	11424-14 06-Oct-2014	Seller
SALAGEN	Egypt	Registered	266459 25-Oct-2011	266459 12-Dec-2016	Seller

Mark	Country	Status	App. No. Date	Reg. No. Date	Owner
SALAGEN	European Union	Registered	000381780 10-Oct-1996*	000381780 31-May-2001	Seller
SALAGEN	France	Registered	283248 29-Apr-1991	1659008 29-Apr-1991	Seller
SALAGEN	Georgia	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Germany	Registered	M69867/SWz 30-Apr-1991	2104818 08-May-1998	Seller
SALAGEN	Greece	Registered	104993 12-Jul-1991	104993 17-Nov-1994	Seller
SALAGEN	Iceland	IR Accepted	473/2004 12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	International Registration (Madrid Protocol)	Registered	12-Nov-2003	817299 2-Nov-2003	Seller
SALAGEN	Israel	Registered	97129 17-Feb-1995	97129 04-Mar-1997	Seller
SALAGEN	Italy	Registered	91C001199 30-May-1991	944937 17-Nov-1993	Seller
SALAGEN	Japan	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN (Roman & Katakana)	Japan	Registered	09-111669 28-Apr-1997	4348403 24-Dec-1999	Seller
SALAGEN (Katakana)	Japan	Registered	09-111668 28-Apr-1997	4516982 26-Oct-2001	Seller
SALAGEN	Kenya	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Korea, South	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN (in Korean Characters)	Korea, South	Registered	40-2012-79206 21-Dec-2012	40-0994818 12-Sep-2013	Seller
SALAGEN	Lesotho	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Liechtenstein	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Macedonia	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Moldova	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Monaco	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Mongolia	IR Accepted	40-M-0817299 12-Nov-2003	IR 817299 12-Nov-2003	Seller

Mark	Country	Status	App. No. Date	Reg. No. Date	Owner
SALAGEN	Morocco	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Mozambique	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Peru	Registered	646998 12-Jan-2016	236479 19-Apr-2016	Seller
SALAGEN	Portugal	Registered	273642 14-May-1991	273642 06-Apr-1993	Seller
SALAGEN	Romania	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Sierra Leone	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Singapore	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	South Africa	Registered	96/11760 21-Aug-1996	96/11760 05-Aug-1999	Seller
SALAGEN	Spain	Registered	1636419 17-May-1991	1636419 04-Mar-1994	Seller
SALAGEN	Swaziland	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Switzerland	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Turkey	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Turkmenistan	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	Ukraine	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller
SALAGEN	United Kingdom	Registered	UK00003308038 02-May-2018	UK00003308038 27-Jul-2018	Seller
SALAGEN	United States	Registered	7412060 04-Dec-1990	1753114 16-Feb-1993	Seller
SALAGEN	Venezuela	Registered	2011-002718 23-Feb-2011	P-314260 13-Dec-2011	Seller
SALAGEN	Zambia	IR Accepted	12-Nov-2003	IR 817299 12-Nov-2003	Seller

Schedule of PANRETIN Product Trademarks

Trademark Applications and Registrations:

Mark	Country	Status	App. No. Date	Reg. No. Date	Owner
PANRETIN	United States	Registered	74700355 12-JUL-1995	2149627 07-APR-1998	Seller

CONFIRMATORY TRADEMARK ASSIGNMENT

This Confirmatory Trademark Assignment (this "Confirmatory Assignment") is made effective as of the 31st day of March, 2019, by and between (i) Concordia Pharmaceuticals Inc., ("CPI") a *societe a responsabilite limitee* (private limited liability company) duly continued and validly existing under the laws of the Grand-Duchy of Luxembourg, having its registered office at 8-10 Avenue de la Gare - L-1610 Luxembourg, Grand-Duchy of Luxembourg, and registered with the Registre de commerce et des societies, Luxembourg (register of trade and companies), by way of its Barbados branch, carrying on business at 5 Canewood Business Centre, St. Michael, Barbados, BB 11005, (ii) Mercury Pharma Group Limited, ("MPGL") a private limited company incorporated in England and Wales, whose registered office is at Capital House, 1st Floor, 85 King William Street, London EC4N 7BL, and (iii) Amdipharm Mercury International Limited, ("AMIL") a private limited company incorporated in Jersey, whose registered office is at 11-15 Seaton Place, St. Helier, Jersey, JE4 0QH (collectively, "Buyer").

RECITALS

WHEREAS, Buyer and Eisai Inc. ("Eisai" or "Seller") have entered into that certain Trademark Assignment Agreement, dated as of March 31, 2019 (the "Original Assignment");

WHEREAS, in connection with the Original Assignment, Seller was the owner in the applicable jurisdiction of the marks, registrations and applications set forth on Schedule A attached thereto and made part thereof and the goodwill of the business associated with and symbolized by such marks (collectively, the "US Exclusive Product Trademarks"); and

WHEREAS in connection with the Original Assignment, Seller sold, assigned, transferred, conveyed and delivered to CPI, MPGL and AMIL, jointly, all of its rights, title and interest in and to the US Exclusive Product Trademarks in the jurisdiction set forth opposite each such US Exclusive Product Trademark on Schedule A therein.

NOW, THEREFORE, in nominal consideration of £1, and other good and valuable consideration, for each of the three conveyances made herein and set forth in Schedule A, Schedule B and Schedule C, CPI, MPGL and AMIL, intending to be legally bound, hereby agree as follows:

1. **Defined Terms.** Unless otherwise specifically provided herein, capitalized terms used in this Confirmatory Assignment and not otherwise defined herein shall have the respective meaning ascribed thereto in the Original Assignment.
2. **Original Intention.** In accordance with the provisions of the Original Assignment, it was the original intention of CPI, MPGL and AMIL that the US Exclusive Product Trademarks be divided between each of CPI, MPGL and AMIL and allocated as set forth in Schedule A, Schedule B and Schedule C attached hereto and made part hereof.
3. **Conveyance and Acceptance of Exclusive Product Trademarks.** To the extent necessary in order to vest the US Exclusive Product Trademarks in each of CPI, MPGL and AMIL in each case with full title guarantee, CPI and MPGL jointly assign to AMIL;

CPI and AMIL jointly assign to MPGL; and MPGL and AMIL jointly assign to CPI all of their respective rights, title and interest to the US Exclusive Product Trademarks in the jurisdiction set forth opposite each such US Exclusive Product Trademark as outlined in Schedule A, Schedule B, and Schedule C attached hereto and made part hereof, including:

- (a) the goodwill of the business relating to the goods or services in respect of which the US Exclusive Product Trademarks are registered or used; and
- (b) the right to bring, make, oppose, defend, appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action (including passing off) arising from ownership, of any of the US Exclusive Product Trademarks occurring before the date of this Confirmatory Assignment.

- 4. **Recordation.** CPI, MPGL and AMIL hereby authorize each other to record this Confirmatory Assignment with the U.S. Patent and Trademark Office and other relevant Governmental Authorities. All costs and expenses, including Third Party filing and recordation fees and other disbursements, associated with the conveyance of the US Exclusive Product Trademarks and with the recordation of this Confirmatory Assignment shall be borne solely by CPI, MPGL and AMIL as applicable.
- 5. **Further Assurances.** CPI, MPGL and AMIL agree to take such further action and to execute and deliver such additional instruments and documents as each of CPI, MPGL and AMIL may reasonably request to carry out and fulfill the purposes and intent of this Confirmatory Assignment, including signing all papers and documents, taking all lawful oaths and doing all acts necessary or required to be done for the procurement, maintenance, and enforcement and defense of trademarks or applications of the US Exclusive Product Trademarks.
- 6. **Miscellaneous.**
 - (a) **Expenses.** All costs and expenses associated with the conveyance under this Confirmatory Assignment of all rights, title and interest of CPI, MPGL and AMIL in and to the US Exclusive Product Trademarks shall be borne solely by CPI, MPGL and AMIL.
 - (b) **Counterparts.** This Confirmatory Assignment may be executed in any number of counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement. Delivery of an executed counterpart of a signature page of this Confirmatory Assignment by facsimile or other electronic transmission shall be effective as delivery of a manually executed original counterpart of this Confirmatory Assignment.

[Signature page follows]

IN WITNESS WHEREOF, the undersigned have duly executed this Confirmatory Assignment, as of the date first above written.


CONCORDIA PHARMACEUTICALS INC.

By: _____
Name: ADEEL AHMAD
Title: DIRECTOR


MERCURY PHARMA GROUP LIMITED

By: _____
Name: ADEEL AHMAD
Title: DIRECTOR

AMDIPHARM MERCURY INTERNATIONAL LIMITED

By: _____
Name: MJ Cullen
Title: Director

Attested by



SHAUN FREDERICK RYAN
Notary Public
1st Floor, Mielles House
La Rue Des Mielles
St Helier
Jersey JE2 3QD
Channel Islands
Main: 01534 764304 / 300
Mob: 07797836478
Email: notarysryan@gmail.com

[Signature page to Confirmatory Trademark Assignment]


PARISH OF London

COUNTRY OF England


On this 07th day of July, 2019, before me personally appeared ADEEL AHMAD.

who, being duly sworn, did say that he/she is the Managing Director, Vice President Legal Affairs of Concordia Pharmaceuticals Inc., Barbados branch and that he/she duly executed the foregoing instrument for and on behalf of Concordia Pharmaceuticals Inc., Barbados branch being duly authorized to do so and that said individual acknowledged said instrument to be the free act and deed of said company.

Notary Public: _____



Expiration Date: FOR LIFE



Kunupath Sathyanath Sreekumar
Notary Public


England & Wales

Date: 07-10-2019
protocol no: 016 - 2019
email: info@holbornotary.com

STATE OF _____ } **SHAUN FREDERICK RYAN**
 } ss Notary Public
COUNTY OF _____ } **St. Helier**
 } **Jersey**

On this 4TH day of OCTOBER, 2019, before me personally appeared MJ CULLEN,
who, being duly sworn, did say that he/she is the DIRECTOR of Amdipharm Mercury
International Limited and that he/she duly executed the foregoing instrument for and on behalf of
Amdipharm Mercury International Limited being duly authorized to do so and that said
individual acknowledged said instrument to be the free act and deed of said company.

Notary Public: Shaun Ryan
Expiration Date: When I do



SHAUN FREDERICK RYAN
Notary Public
1st Floor, Mielles House
La Rue des Mielles
St Helier
Jersey JE2 3QD
Channel Islands
Main: 01534 764304 / 300
Mob: 07797836478
Email: notarysryan@gmail.com

SL 6531

SCHEDULE A

US EXCLUSIVE PRODUCT TRADEMARKS

Schedule of SALAGEN Product Trademarks Assigned from CPI and MPGL to AMIL

Trademark Applications and Registrations:

Mark	Country	App. No. Date	Reg. No. Date	Owner Under Original Assignment	Owner Under This Confirmatory Assignment
SALAGEN	Albania	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Andorra	2000 19-Dec-1996	1470 19-Dec-1996	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Antigua and Barbuda	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Argentina	3062975 19-Jan-2011	2738487 13-Jul-2015	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Armenia	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Australia	715002 13-Aug-1996	715002 19-Sep-1997	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Australia	988334 12-Nov-2003	988334 (IR 817299) 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Belarus	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Benelux	763095 26-Apr-1991	495933 26-Apr-1991	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Bhutan	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Brazil	819666394 02-Dec-1996	819666394 04-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL

SALAGEN	Bulgaria	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	China	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Colombia	10030242 5-Mar-2010	428118 29-Jun-2011	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Cuba	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Denmark	3149/91 01-May-1991	2681-1993 02-Apr-1993	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Ecuador	2013-35199 08-Feb-2013	11424-14 06-Oct-2014	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Egypt	266459 25-Oct-2011	266459 12-Dec-2016	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	European Union	000381780 10-Oct-1996	000381780 31-May- 2001	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	France	283248 29-Apr-1991	1659008 29-Apr-1991	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Georgia	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Germany	M69867/5Wz 30-Apr-1991	2104818 08-May- 1998	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Greece	104993 12-Jul-1991	104993 17-Nov-1994	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Iceland	473/2004 12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	International Registration (Madrid Protocol)	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Israel	97129 17-Feb-1995	97129 04-Mar-1997	MPGL, AMIL, and CPI, jointly	AMIL

SALAGEN	Italy	91C001199 30-May-1991	944937 17-Nov-1993	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Japan	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN (Roman & Katakana)	Japan	09-111669 28-Apr-1997	4348403 24-Dec-1999	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN (Katakana)	Japan	09-111668 28-Apr-1997	4516982 26-Oct-2001	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Kenya	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Korea, South	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN (in Korean Characters)	Korea, South	40-2012-79206 21-Dec-2012	40-0994818 12-Sep-2013	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Lesotho	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Liechtenstein	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Macedonia	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Moldova	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Monaco	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Mongolia	40-M-0817299 12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Morocco	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Mozambique	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL

SALAGEN	Peru	646998 12-Jan-2016	236479 19-Apr-2016	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Portugal	273642 14-May-1991	273642 06-Apr-1993	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Romania	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Sierra Leone	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Singapore	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	South Africa	96/11760 21-Aug-1996	96/11760 05-Aug-1999	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Spain	1636419 17-May-1991	1636419 04-Mar-1994	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Swaziland	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Switzerland	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Turkey	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Turkmenistan	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Ukraine	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Venezuela	2011-002718 23-Feb-2011	P-314260 13-Dec-2011	MPGL, AMIL, and CPI, jointly	AMIL
SALAGEN	Zambia	12-Nov-2003	IR 817299 12-Nov-2003	MPGL, AMIL, and CPI, jointly	AMIL

SCHEDULE B

US EXCLUSIVE PRODUCT TRADEMARKS

Schedule of SALAGEN Product Trademarks Assigned from CPI and AMIL to MPGL

Trademark Applications and Registrations:

Mark	Country	App. No. Date	Reg. No. Date	Owner Under Original Assignment	Owner Under This Confirmatory Assignment
SALAGEN	Canada	0680671 24-Apr-1991	TMA440724 24-Mar-1995	MPGL, AMIL, and CPI, jointly	MPGL
SALAGEN	United Kingdom	UK00003308038 02-May-2018	UK00003308038 27-Jul-2018	MPGL, AMIL, and CPI, jointly	MPGL

SCHEDULE C

US EXCLUSIVE PRODUCT TRADEMARKS

Schedule of SALAGEN Product Trademarks Assigned from MPGL and AMIL to CPI

Trademark Applications and Registrations:

Mark	Country	App. No. Date	Reg. No. Date	Owner Under Original Assignment	Owner Under This Confirmatory Assignment
SALAGEN	United States	7412060 04-Dec-1990	1753114 16-Feb-1993	MPGL, AMIL, and CPI, jointly	CPI

Schedule of PANRETIN Product Trademarks Assigned from MPGL and AMIL to CPI

Trademark Applications and Registrations:

Mark	Country	App. No. Date	Reg. No. Date	Owner Under Original Assignment	Owner Under This Confirmatory Assignment
PANRETIN	United States	74700355 12-Jul-1995	2149627 07-Apr-1998	MPGL, AMIL, and CPI, jointly	CPI